Century Therapeutics Inc IPSC
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-06-17 |
| Shares Out. | 180,350,000 |
| Website | centurytx.com/ ↗ |
| Phone | 12159814000 |
| Employees | 78 |
| Net Income | -$21.6M |
| Free Cash Flow | -$95.5M |
| Total Assets | $326.6M |
| Total Liabilities | $61.8M |
| Equity | $264.7M |
About Century Therapeutics Inc
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Century Therapeutics Inc is a publicly traded company under the ticker symbol IPSC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)